Blueprint
UNITED
STATES SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of February 2017.
Commission File
Number: 000-53805
Intellipharmaceutics International
Inc.
(Translation of registrant’s name into English)
30
WORCESTER ROAD TORONTO, ONTARIO M9W 5X2
(Address of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F. Form 20-F [ x ] Form
40-F [ ]
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Note: Regulation S-T Rule 101(b)(1) only permits the
submission in paper of a Form 6-K if submitted solely to provide an
attached annual report to security holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7):
Note: Regulation S-T Rule 101(b)(7) only permits the
submission in paper of a Form 6-K if submitted to furnish a report
or other document that the registrant foreign private issuer must
furnish and make public under the laws of the jurisdiction in which
the registrant is incorporated, domiciled or legally organized (the
registrant’s “home country”), or under the rules
of the home country exchange on which the registrant’s
securities are traded, as long as the report or other document is
not a press release, is not required to be and has not been
distributed to the registrant’s security holders, and, if
discussing a material event, has already been the subject of a Form
6-K submission or other Commission filing on
EDGAR.
This
Report of Foreign Private Issuer on Form 6-K and the attached
exhibits 23.1, 23.2, 99.1, 99.2 and 101 shall be incorporated by
reference into the Company’s effective Registration
Statements on Form F-3, as amended and supplemented (Registration
Statement Nos. 333-172796 and 333-196112), filed with the
Securities and Exchange Commission, from the date on which this
Report is filed, to the extent not superseded by documents or
reports subsequently filed or furnished by Intellipharmaceutics
International Inc. under the Securities Act of 1933 or the
Securities Exchange Act of 1934.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Intellipharmaceutics
International Inc.
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
Date:
February 9, 2017
|
/s/
Domenic Della Penna
|
|
|
Domenic
Della Penna
|
|
|
Chief Financial Officer
|
EXHIBIT LIST
23.1
Consent
of Independent Registered Public Accounting Firm (MNP
LLP)
23.2
Consent
of Independent Registered Public Accounting Firm (Deloitte
LLP)
99.1
Management
Discussion and Analysis of Financial Condition and Results of
Operations for the Year Ended November 30, 2016
99.2
Consolidated
Financial Statements and Notes to Consolidated Financial Statements
of Intellipharmaceutics International Inc. for the Year Ended
November 30, 2016
99.3
News
Release dated February 10, 2017 - Intellipharmaceutics Announces
2016 Year End Results
101
XBRL
(Extensible Business Reporting Language). The following materials
from Intellipharmaceutics International Inc.’s Consolidated
Financial Statements and Notes to the Consolidated Financial
Statements for the fiscal year-ended November 30, 2016, formatted
in XBRL:
(i)
Consolidated
balance sheets as at November 30, 2016 and 2015
(ii)
Consolidated
statements of operations and comprehensive loss for the years ended
November 30, 2016, 2015 and 2014
(iii)
Consolidated
statements of shareholders’ equity (deficiency) for the years
ended November 30, 2016, 2015 and 2014
(iv)
Consolidated
statements of cash flows for the years ended November 30, 2016,
2015 and 2014
(v)
Notes
to the consolidated financial statements